Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maura Rossi

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy studyPier Paolo Piccaluga, Fabio Fuligni, Antonio De Leo, et al.
Molecular Cancer Research : MCR|January 29, 2017
Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell SarcomasMaria Antonella Laginestra, Claudio Tripodo, Claudio Agostinelli, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Laura Arenare, Alessandro Morabito, et al.
Haematologica|November 2, 2018
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic targetMaria Rosaria Sapienza, Francesco Abate, Federica Melle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Endocrine-Related Cancer|March 17, 2023
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy studyPier Paolo Piccaluga, Fabio Fuligni, Antonio De Leo, et al.
Molecular Cancer Research : MCR|January 29, 2017
Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell SarcomasMaria Antonella Laginestra, Claudio Tripodo, Claudio Agostinelli, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Leukemia & Lymphoma|April 5, 2018
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiFrancesco Zaja, Flavia Salvi, Maura Rossi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patientsMaria Lucia Iacovino, Laura Arenare, Alessandro Morabito, et al.
Haematologica|November 2, 2018
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic targetMaria Rosaria Sapienza, Francesco Abate, Federica Melle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Endocrine-Related Cancer|March 17, 2023
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE studyNicola Fazio, Lorenzo Gervaso, Thorvardur R Halfdanarson, et al.
Pageof 8